Vildagliptin was generally shown to have a beneficial or neutral effect on lipid parameters; however, one study reported a small decrease in HDL cholesterol levels, ...

The DPP-IV inhibitor vildagliptin did not increase the likelihood of cardiovascular death, myocardial infarction, stroke and other CV outcomes in adults with type 2 diabetes and recent CV ...

A recent study has found that a single dose of the DPP-IV inhibitor vildagliptin caused a significant suppression of endogenous glucose production in patients with type 2 diabetes.

Vildagliptin (trade name Galvus or Jalra) has been approved since September 2007 for adults with type 2 diabetes mellitus in whom diet and exercise do not provide adequate glycaemic control.

(HealthDay)—The dipeptidyl peptidase-4 (DPP-4) inhibitors vildagliptin and sitagliptin have similar effects on incretin hormone secretion, according to a study published online June 14 in ...

Combination vildagliptin and metformin can improve glycemic control in Japanese patients with type 2 diabetes mellitus (T2DM) without inducing tolerability issues or hypoglycemia, a new study ...

Vildagliptin (trade name Galvus or Jalra) has been approved since September 2007 for adults with type 2 diabetes mellitus in whom diet and exercise do not provide adequate glycaemic control. The ...

If vildagliptin is approved for marketing, it will add to the available treatment options for diabetes and will provide patients and health care providers with another noninjectable therapy option.

Vildagliptin (trade name Galvus or Jalra) has been approved since September 2007 for adults with type 2 diabetes mellitus in whom diet and exercise do not provide adequate glycaemic control.